Insider · CIK 0001276840
Dennis Mulroy
Files at ANAB (ANAPTYSBIO, INC), ARCT (Arcturus Therapeutics Holdings Inc.). First filing Dec 18, 2025, latest Jan 9, 2026.
Dennis Mulroy files SEC Form 4 as CFO at ANAB (ANAPTYSBIO, INC), and also at ARCT (Arcturus Therapeutics Holdings Inc.). Since Dec 18, 2025, Dennis Mulroy has reported 0 open-market buys worth $0 and 5 open-market sells worth $1.5M, the latest filed on Jan 9, 2026.
A track record needs three past buys with six months of prices behind them; Dennis Mulroy has 0, so none is measured yet.
The newest scored trade: sold $112k of ANAB on Jan 8, 2026, filed Jan 9, 2026, scored 37 (weak). In the last 12 months: 0 buys worth $0 and 5 sells worth $1.5M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ANAB: ANAPTYSBIO, INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | ANAPTYSBIO, INC | $112k 2,515 shares | -10% | +254% from low-14% from high | |
| 31Weak | ANAPTYSBIO, INC | $86k 1,908 shares | -10% | +265% from low-11% from high | |
| 38Weak | ANAPTYSBIO, INC | $145k 3,363 shares | -19% | +249% from low-15% from high | |
| 40Moderate | ANAPTYSBIO, INC | $500k 10,000 shares | -52% | +307% from low0% from high | |
| 43Moderate | ANAPTYSBIO, INC | $705k 15,725 shares | -63% | +264% from low-2% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 9, 2026 | ANAB ANAPTYSBIO, INC | 2,515 0.01% of outstanding | $114k | Jan 8, 2026 | $2.8M |
| Jan 8, 2026 | ANAB ANAPTYSBIO, INC | 1,908 0.01% of outstanding | $84k | Jan 7, 2026 | $2.7M |
| Jan 6, 2026 | ANAB ANAPTYSBIO, INC | 3,363 0.01% of outstanding | $151k | Jan 5, 2026 | $1.2M |
| Dec 22, 2025 | ANAB ANAPTYSBIO, INC. | 10,000 0.04% of outstanding | $500k | Dec 22, 2025 | $705k |
| Dec 16, 2025 | ANAB ANAPTYSBIO, INC. | 15,725 0.06% of outstanding | $705k | Dec 16, 2025 | none |
Transactions
Every row this insider has filed, 27 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | ARCT Arcturus Therapeutics Holdings Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | May 7, 2026 |
| Jan 7, 2026 | ANAB ANAPTYSBIO, INC | MOption exercise Common Stock | +6,700 | - | - | 24,367 | Jan 9, 2026 |
| Jan 8, 2026 | ANAB ANAPTYSBIO, INC | SOpen-market sale Common Stock | -2,515 | $44.71 | $112k | 21,852 | Jan 9, 2026 |
| Jan 7, 2026 | ANAB ANAPTYSBIO, INC | MOption exercise Restricted Stock Unitderivative | -6,700 | $0.00 | $0 | 20,100 | Jan 9, 2026 |
| Jan 6, 2026 | ANAB ANAPTYSBIO, INC | MOption exercise Common Stock | +5,245 | - | - | 19,575 | Jan 8, 2026 |
| Jan 7, 2026 | ANAB ANAPTYSBIO, INC | SOpen-market sale Common Stock | -1,908 | $45.11 | $86k | 17,667 | Jan 8, 2026 |
| Jan 6, 2026 | ANAB ANAPTYSBIO, INC | MOption exercise Restricted Stock Unitderivative | -5,245 | $0.00 | $0 | 5,245 | Jan 8, 2026 |
| Jan 6, 2026 | ANAB ANAPTYSBIO, INC | AGrant or award Restricted Stock Unitderivative | +21,400 | $0.00 | $0 | 21,400 | Jan 8, 2026 |
| Jan 6, 2026 | ANAB ANAPTYSBIO, INC | AGrant or award Stock Option (right to buy)derivative | +29,000 | $0.00 | $0 | 29,000 | Jan 8, 2026 |
| Jan 3, 2026 | ANAB ANAPTYSBIO, INC | MOption exercise Common Stock | +8,292 | - | - | 17,693 | Jan 6, 2026 |
| Jan 5, 2026 | ANAB ANAPTYSBIO, INC | SOpen-market sale Common Stock | -3,363 | $43.26 | $145k | 14,330 | Jan 6, 2026 |
| Jan 3, 2026 | ANAB ANAPTYSBIO, INC | MOption exercise Restricted Stock Unitderivative | -8,292 | $0.00 | $0 | 16,585 | Jan 6, 2026 |
| Dec 22, 2025 | ANAB ANAPTYSBIO, INC | MOption exercise Common Stock10b5-1 | +10,000 | $20.16 | $202k | 19,401 | Dec 23, 2025 |
| Dec 22, 2025 | ANAB ANAPTYSBIO, INC | SOpen-market sale Common Stock10b5-1 | -10,000 | $50.00 | $500k | 9,401 | Dec 23, 2025 |
| Dec 22, 2025 | ANAB ANAPTYSBIO, INC | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 60,600 | Dec 23, 2025 |
| Dec 16, 2025 | ANAB ANAPTYSBIO, INC | MOption exercise Common Stock10b5-1 | +10,000 | $20.16 | $202k | 25,126 | Dec 18, 2025 |
| Dec 16, 2025 | ANAB ANAPTYSBIO, INC | SOpen-market sale Common Stock10b5-1 | -9,365 | $44.62 | $418k | 15,761 | Dec 18, 2025 |
| Dec 16, 2025 | ANAB ANAPTYSBIO, INC | SOpen-market sale Common Stock10b5-1 | -6,360 | $45.21 | $288k | 9,401 | Dec 18, 2025 |
| Dec 16, 2025 | ANAB ANAPTYSBIO, INC | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 70,600 | Dec 18, 2025 |
| Jan 3, 2025 | ANAB ANAPTYSBIO, INC | MOption exercise Common Stock | +8,293 | - | - | 14,018 | Jan 7, 2025 |
| Jan 3, 2025 | ANAB ANAPTYSBIO, INC | FTax withholding Common Stock | -3,407 | $14.60 | $50k | 10,611 | Jan 7, 2025 |
| Jan 6, 2025 | ANAB ANAPTYSBIO, INC | MOption exercise Common Stock | +5,245 | - | - | 15,856 | Jan 7, 2025 |
| Jan 6, 2025 | ANAB ANAPTYSBIO, INC | FTax withholding Common Stock | -2,054 | $15.30 | $31k | 13,802 | Jan 7, 2025 |
| Jan 3, 2025 | ANAB ANAPTYSBIO, INC | MOption exercise Restricted Stock Unitderivative | -8,293 | $0.00 | $0 | 24,877 | Jan 7, 2025 |
| Jan 6, 2025 | ANAB ANAPTYSBIO, INC | MOption exercise Restricted Stock Unitderivative | -5,245 | $0.00 | $0 | 10,490 | Jan 7, 2025 |
| Jan 7, 2025 | ANAB ANAPTYSBIO, INC | AGrant or award Restricted Stock Unitderivative | +26,800 | $0.00 | $0 | 26,800 | Jan 7, 2025 |
| Jan 7, 2025 | ANAB ANAPTYSBIO, INC | AGrant or award Stock Option (right to buy)derivative | +76,400 | $0.00 | $0 | 76,400 | Jan 7, 2025 |
Questions about Dennis Mulroy
Answered from the filings on this page, as of the latest one.
Is Dennis Mulroy buying or selling?
In the last 12 months Dennis Mulroy reported 0 open-market buys worth $0 and 5 open-market sells worth $1.5M on SEC Form 4; the latest was sold $112k of ANAB on Jan 8, 2026. Grants, option exercises and tax withholding are not counted.
How did Dennis Mulroy's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Dennis Mulroy has 0.
Where does Dennis Mulroy file Form 4?
Dennis Mulroy has filed Form 4 at ANAB (ANAPTYSBIO, INC) as CHIEF FINANCIAL OFFICER; ARCT (Arcturus Therapeutics Holdings Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.